The vision of CannaCor is to become a frontrunner of medical cannabis cultivation in Lesotho. Their focus is to implement sustainable production facilities and expand their lead with an aquaponics production plant while integrating all their management systems with a selection of blockchain technologies to ensure
transparency, immutability and real-life tracking.
CannaCor works with a group of experienced scientists, blockchain developers, pharmacists and engineers daily, with the goal of improving our company by researching and delivering environmentally sustainable high-quality cannabis products.
The Cannacor Operations
CannaCor operates within the Lesotho cannabis industry. Lesotho legalized the production of cannabis in September 2017 under the Drugs of Abuse Regulations, Act of 2018. Different classes of operating licenses are granted to cultivate cannabis, export manufactured products, and conduct testing, etc.
CannaCor (Pty) Ltd is an incorporated company under the Companies Act of 2011 in the Kingdom of Lesotho and was registered on 16 November 2018 (Registration number 65263), (TIN number 200084029-4). The company is licensed as a prohibited drug operator. The license is granted under Section 12 of the Drug
Abuse Act of 2008 with license number 02/D022/06-2019. CannaCor (Pty) Ltd is licensed to perform certain activities, as defined in the act, namely: the cultivation of cannabis; manufacture of cannabis products; supply and distribution of cannabis; storage of cannabis and/or the export, import and transit of cannabis products
within, into and outside of Lesotho for medicinal purposes and/or scientific use and any other lawful use.
The Cannacor team will ensure that they are compliant with every aspect of the act and are certified by the following: ISO 9001, Good Agricultural and Collecting Practice (GACP), Good Manufacturing Practice (GMP) and Good Laboratory Practice (GLP).
CannaCor has obtained 50 000 m2 of land in Berea, Lesotho, of which 30 000 m2 is permitted for greenhouse or indoor cultivation of cannabis. The remainder of the land will be used for further expansion as demand grows.
A medical cannabis plant will be established to cultivate cannabis and produce products such as:
Oils: Tetrahydrocannabinol (THC), Cannabidiol (CBD), Cannabinoids (CBN), Tetrahydrocannabinolic Acid (THCA) in various strengths and combinations of Cannabis and oil capsules and various other products:
CannaCor intends to commence with the development of an aquaponics production facility for medical cannabis during the fourth quarter of 2019. An aquaponics production facility is a strategically important asset for CannaCor as most other European liberalized markets do not allow for local production and rely on imports. The company will be able to serve Canada, Europe and other global markets from this facility.